A detailed history of Bml Capital Management, LLC transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Bml Capital Management, LLC holds 14,250,000 shares of ACRS stock, worth $29.2 Million. This represents 9.64% of its overall portfolio holdings.

Number of Shares
14,250,000
Previous 12,988,134 9.72%
Holding current value
$29.2 Million
Previous $14.3 Billion 14.7%
% of portfolio
9.64%
Previous 10.2%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$1.12 - $1.4 $1.41 Million - $1.77 Million
1,261,866 Added 9.72%
14,250,000 $16.4 Billion
Q2 2024

Aug 07, 2024

BUY
$1.01 - $1.36 $3.63 Million - $4.89 Million
3,592,200 Added 38.23%
12,988,134 $14.3 Billion
Q1 2024

Apr 23, 2024

BUY
$0.92 - $1.44 $8.04 Million - $12.6 Million
8,742,827 Added 1338.65%
9,395,934 $11.7 Billion
Q4 2023

Jan 30, 2024

BUY
$0.64 - $6.49 $417,988 - $4.24 Million
653,107 New
653,107 $686 Million

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $137M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track Bml Capital Management, LLC Portfolio

Follow Bml Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bml Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bml Capital Management, LLC with notifications on news.